17,261 trials
Atopic Dermatitis
Primary: Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 12 — -10.78; -13.67; -15.14; -15.72 units on a scale — p=0.143
Lymphoma
Primary: Progression-Free Survival (PFS) at 2 Years — 82; 81 percentage of participants
Herpes Zoster
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 6; 2 Participants
Breast Cancer
Primary: Progression-Free Survival (PFS) — 18.89; 15.80; 20.63; 15.80 months — p=0.0070
Retinopathy of Prematurity (ROP)
Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642
Typhoid
Primary: Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions. — 0; 0; 0; 0 Participants
Cocaine Related Disorders
Primary: Cocaine Craving — 4.8; 3.4; 3.0; 2.7 units on a scale
Graft vs Host Disease
Primary: Cummalative Incidence of Grade 2 to 4 Acute Graft vs Host Diesease (GVHD) at Day 100 Post Transplant in HSCT Recipients — 3.3 percentage of participants — p=<0.05
Fasting
Primary: Cortisol — 17.5; 16.9 ug/dl
Sleep Apnea, Obstructive
Primary: Genioglossus Activity During Sleep Expressed as %Wakefulness Value (Before Drug/Placebo Administration). — 166; 136; 245; 163 percentage of wakefulness value — p=0.85
Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic · Leukemia, Lymphoblastic, Acute
Primary: Proportion of Donors From Whom a Sufficient Number of Cells for Transplantation Are Collected in no More Than 2 LP Procedures Following Mobilization With AMD3100 (Donor…
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 39.1; 40.8 events/hour — p=>0.5
Neurofibromatosis 1
Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3
Posttraumatic Stress Disorder · PTSD
Primary: Child PTSD Symptom Scale (CPSS) — 20.4; 11.0 units on a scale
Tobacco Use Disorder · Weight Gain
Primary: Post Cessation Weight Change — 1.1 kg